Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
Acta Dermato-Venereologica · 2025
DOI: 10.2340/actadv.v105.42990 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Acta Dermato-Venereologica, 2025. Verfasst von Sophie C Van Helmond und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Alopecia areata (AA) is an autoimmune hair loss disorder characterized by sudden hair shedding due to immune dysregulation involving the Janus Kinase – Signal Transducer and Activator of Transcription (JAK-STAT) pathway. JAK inhibitors (JAKi) have demonstrated efficacy in clinical trials, but data from real-world settings remain scarce. This retrospective, single-centre cohort study evaluated the real-world effectiveness and safety of JAKi (abrocitinib, baricitinib, ritlecitinib, upadacitinib, and tofacitinib) in 72 patients treated between December 2017 and February 2024. Patients had a mean age of 34 years and a mean disease duration of 8 years. At time points 3, 6, 9, 12, and 18 months substantial regrowth was observed in 18 (25%), 28 (38.9%), 25 (34.7%), 22 (30.6%), and 19 (26.4%) patients respectively. Over a median follow-up of 16 months, 61% achieved substantial regrowth at a median time of 7 months. At 3, 6, 9, and 12 months, the cumulative regrowth rates were 11.1%, 40.2%, 55.6%, and 59.7%, respectively. Among non-responders who switched medications, 75% achieved substantial regrowth. Two serious adverse events occurred (sickle cell crisis and renal failure with pre-existing dysfunction). The findings indicate that JAKi are effective and safe for AA treatment in real-world settings. Further prospective studies are necessary to optimize treatment guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
- Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands. r.waalboer@erasmusmc.nl.
- Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands; Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands.
Zitieren
APA
Van Helmond, S. C., Willaert, M., Nguyen, V. H., Nijsten, T., Waalboer-Spuij, R., & Hijnen, D. (2025). Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v105.42990
Vancouver
Van Helmond SC, Willaert M, Nguyen VH, Nijsten T, Waalboer-Spuij R, Hijnen D. Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients. Acta Dermato-Venereologica. 2025. doi:10.2340/actadv.v105.42990
BibTeX
@article{VanHelmond2025,
author = {Van Helmond, Sophie C and Willaert, Mathias and Nguyen, Viet-Hoa and Nijsten, Tamar and Waalboer-Spuij, Rick and Hijnen, DirkJan},
title = {Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients},
journal = {Acta Dermato-Venereologica},
year = {2025},
doi = {10.2340/actadv.v105.42990}
}
EUVIMED